PRESS RELEASE

Q3 2024 — Press release

Q3 2024PDF · 23 pages1.6 MB
For immediate release

-- 1 of 23 --



-- 2 of 23 --

$10.05
$0.10
$10.15
($0.24)
$9.91

-- 3 of 23 --

5.7% – 6.2% / 6.0% 5.5% – 6.0% / 5.8%
$89.4B – $89.8B / $89.6B
6.3% – 6.8% / 6.6%
$89.2B – $89.6B / $89.4B
6.1% – 6.6% / 6.4%
$88.4B – $88.8B / $88.6B
5.1% – 5.6% / 5.4%
$88.0B – $88.4B / $88.2B
4.7% – 5.2% / 5.0%
$9.86 – $9.96 / $9.91
(0.6)% – 0.4% / (0.1)%
$10.00 – $10.10 / $10.05
0.8% – 1.8% / 1.3%
$9.88 – $9.98 / $9.93
(0.4)% – 0.6% / 0.1%
$9.97 – $10.07 / $10.02
0.5% – 1.5% / 1.0%

-- 4 of 23 --



-- 5 of 23 --



-- 6 of 23 --



-- 7 of 23 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine (1)
U.S. 8,871	$ 8,249 7.5 % 7.5 - 24,993	$ 23,090 8.2 % 8.2 -
International 5,709 5,644 1.2 4.4 (3.2) 17,639 17,947 (1.7) 2.1 (3.8)
14,580 13,893 4.9 6.3 (1.4) 42,632 41,037 3.9 5.5 (1.6)
Innovative Medicine excluding COVID-19 Vaccine (1)
U.S. 8,871 8,249 7.5 7.5 - 24,993 23,090 8.2 8.2 -
International 5,708 5,603 1.9 5.2 (3.3) 17,441 16,874 3.4 7.4 (4.0)
14,579 13,852 5.2 6.6 (1.4) 42,434 39,964 6.2 7.9 (1.7)
MedTech
U.S. 4,038 3,747 7.8 7.8 - 12,105 11,345 6.7 6.7 -
International 3,853 3,711 3.9 5.0 (1.1) 11,564 11,382 1.6 4.7 (3.1)
7,891 7,458 5.8 6.4 (0.6) 23,669 22,727 4.1 5.7 (1.6)
U.S. 12,909 11,996 7.6 7.6 - 37,098 34,435 7.7 7.7 -
International 9,562 9,355 2.2 4.6 (2.4) 29,203 29,329 (0.4) 3.1 (3.5)
Worldwide 22,471 21,351 5.2 6.3 (1.1) 66,301 63,764 4.0 5.6 (1.6)
U.S. 12,909 11,996 7.6 7.6 - 37,098 34,435 7.7 7.7 -
International 9,561 9,314 2.7 5.1 (2.4) 29,005 28,256 2.7 6.3 (3.6)
Worldwide excluding COVID-19 Vaccine (1)	
22,470	$ 21,310 5.4 % 6.5 (1.1) 66,103	$ 62,691 5.4 % 7.1 (1.7)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
THIRD QUARTER NINE MONTHS
Percent Change

-- 8 of 23 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
geographic area
U.S. 12,909	$ 11,996 7.6 % 7.6 - 37,098	$ 34,435 7.7 % 7.7 -
Europe 4,914 4,727 4.0 3.0 1.0 15,291 15,448 (1.0) (0.7) (0.3)
Western Hemisphere excluding U.S. 1,173 1,171 0.3 20.3 (20.0) 3,579 3,383 5.8 21.4 (15.6)
Asia-Pacific, Africa 3,475 3,457 0.5 1.5 (1.0) 10,333 10,498 (1.6) 2.8 (4.4)
International 9,562 9,355 2.2 4.6 (2.4) 29,203 29,329 (0.4) 3.1 (3.5)
Worldwide 22,471	$ 21,351 5.2 % 6.3 (1.1) 66,301	$ 63,764 4.0 % 5.6 (1.6)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Sales to customers by
geographic area (ex. COVID-19 Vaccine)
U.S.* 12,909	$ 11,996 7.6 % 7.6 - 37,098	$ 34,435 7.7 % 7.7 -
Europe(1) 4,913 4,686 4.8 3.8 1.0 15,093 14,375 5.0 5.3 (0.3)
Western Hemisphere excluding U.S.* 1,173 1,171 0.3 20.3 (20.0) 3,579 3,383 5.8 21.4 (15.6)
Asia-Pacific, Africa* 3,475 3,457 0.5 1.5 (1.0) 10,333 10,498 (1.6) 2.8 (4.4)
International 9,561 9,314 2.7 5.1 (2.4) 29,005 28,256 2.7 6.3 (3.6)
Worldwide 22,470	$ 21,310 5.4 % 6.5 (1.1) 66,103	$ 62,691 5.4 % 7.1 (1.7)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales information schedules
*No COVID-19 Vaccine sales
Percent Change
THIRD QUARTER NINE MONTHS
Percent Change
THIRD QUARTER NINE MONTHS

-- 9 of 23 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 22,471	$ 100.0 21,351	$ 100.0 5.2
Cost of products sold 6,963 31.0 6,606 30.9 5.4
Gross Profit 15,508 69.0 14,745 69.1 5.2
Selling, marketing and administrative expenses 5,478 24.3 5,400 25.3 1.4
Research and development expense 4,952 22.0 3,447 16.2 43.7
In-process research and development impairments - - 206 1.0
Interest (income) expense, net (99) (0.4) (182) (0.8)
Other (income) expense, net 1,798 8.0 499 2.3
Restructuring 41 0.2 158 0.7
Earnings before provision for taxes on income 3,338 14.9 5,217 24.4 (36.0)
Provision for taxes on income 644 2.9 908 4.2 (29.1)
Net earnings from Continuing Operations 2,694	$ 12.0 4,309	$ 20.2 (37.5)
Net earnings from Discontinued Operations, net of tax - 21,719
Net earnings 2,694	$ 26,028	$
Net earnings per share (Diluted) from Continuing Operations 1.11	$ 1.69	$ (34.3)
Net earnings per share (Diluted) from Discontinued Operations -	$ 8.52	$
Average shares outstanding (Diluted) 2,427.9 2,549.7
Effective tax rate from Continuing Operations 19.3 % 17.4 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 7,277	$ 32.4 8,033	$ 37.6 (9.4)
Net earnings from Continuing Operations 5,876	$ 26.1 6,777	$ 31.7 (13.3)
Net earnings per share (Diluted) from Continuing Operations 2.42	$ 2.66	$ (9.0)
Effective tax rate from Continuing Operations 19.3 % 15.6 %
(1) See Reconciliation of Non-GAAP Financial Measures.
THIRD QUARTER
2024 2023

-- 10 of 23 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 66,301	$ 100.0 63,764	$ 100.0 4.0
Cost of products sold 20,343 30.7 19,755 31.0 3.0
Gross Profit 45,958 69.3 44,009 69.0 4.4
Selling, marketing and administrative expenses 16,416 24.8 15,702 24.6 4.5
Research and development expense 11,934 18.0 10,605 16.6 12.5
In-process research and development impairments 194 0.3 255 0.4
Interest (income) expense, net (433) (0.7) (277) (0.4)
Other (income) expense, net 4,855 7.3 7,055 11.1
Restructuring 192 0.3 433 0.6
Earnings before provision for taxes on income 12,800 19.3 10,236 16.1 25.0
Provision for taxes on income 2,165 3.3 1,042 1.7 107.8
Net earnings from Continuing Operations 10,635	$ 16.0 9,194	$ 14.4 15.7
Net earnings from Discontinued Operations, net of tax - 21,910
Net earnings 10,635	$ 31,104	$
Net earnings per share (Diluted) from Continuing Operations 4.38	$ 3.53	$ 24.1
Net earnings per share (Diluted) from Discontinued Operations -	$ 8.42	$
Average shares outstanding (Diluted) 2,429.5 2,603.4
Effective tax rate from Continuing Operations 16.9 % 10.2 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 23,558	$ 35.5 23,574	$ 37.0 (0.1)
Net earnings from Continuing Operations 19,296	$ 29.1 19,847	$ 31.1 (2.8)
Net earnings per share (Diluted) from Continuing Operations 7.94	$ 7.62	$ 4.2
Effective tax rate from Continuing Operations 18.1 % 15.8 %
(1) See Reconciliation of Non-GAAP Financial Measures.
NINE MONTHS
2024 2023

-- 11 of 23 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2024 2023 2024 2023
Net Earnings from Continuing Operations, after tax- as reported $2,694 $4,309 $10,635 $9,194
Pre-tax Adjustments
Litigation related 2,388 (51) 5,466 6,986
Intangible Asset Amortization expense 1,171 1,132 3,355 3,384
COVID-19 Vaccine related costs 1 4 44 77 653
Restructuring related 2 47 384 207 659
Medical Device Regulation 3 38 74 157 223
Acquisition, integration and divestiture related 328 22 928 102
(Gains)/losses on securities (37) 1,005 374 1,076
IPR&D impairments - 206 194 255
Tax Adjustments
Tax impact on special item adjustments 4 (762) (482) (2,055) (2,769)
Tax legislation and other tax related 5 134 (42) 84
Adjusted Net Earnings from Continuing Operations, after tax $5,876 $6,777 $19,296 $19,847
Average shares outstanding (Diluted) 2,427.9 2,549.7 2,429.5 2,603.4
Adjusted net earnings per share from Continuing Operations (Diluted) $2.42 $2.66 $7.94 $7.62
Operational adjusted net earnings per share from Continuing Operations (Diluted) $2.41 $7.94
Notes:
1 COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing
network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine
contractual commitments.
2
3
4 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special
items in arriving at adjusted earnings.
Third Quarter Nine Months Ended
is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical
devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-
time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and
consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing
performance which will be completed by the end of 2024.
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment
to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic
areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus
(RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $19 million in the fiscal third quarter of 2024 ($100
million Q3 2024 YTD) and $149 million in the fiscal third quarter of 2023 ($424 million Q3 2023 YTD) includes the termination of partnered and
non-partnered program costs, asset impairments and asset divestments.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline
operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $28 million in the fiscal
third quarter of 2024 ($107 million Q3 2024 YTD) and $235 million in the fiscal third quarter of 2023 ($235 million Q3 2023 YTD) primarily
includes inventory and instrument reserves related to the market and product exits.

-- 12 of 23 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 4.9% 5.8% 5.2%
U.S. 7.5% 7.8% 7.6%
International 1.2% 3.9% 2.2%
WW Currency (1.4) (0.6) (1.1)
U.S. - - -
International (3.2) (1.1) (2.4)
WW Operational 6.3% 6.4% 6.3%
U.S. 7.5% 7.8% 7.6%
International 4.4% 5.0% 4.6%
Shockwave (3.1) (1.1)
U.S. (4.4) (1.4)
International (1.8) (0.7)
All Other Acquisitions and Divestitures (A&D) 0.1 0.4 0.2
U.S. 0.1 0.8 0.3
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 6.4% 3.7% 5.4%
U.S. 7.6% 4.2% 6.5%
International 4.6% 3.2% 4.0%
COVID-19 Vaccine 0.3 0.2
U.S. 0.0 0.0
International 0.8 0.5
WW Adjusted Operational Ex A&D & COVID-19 Vaccine 6.7% 3.7% 5.6%
U.S. 7.6% 4.2% 6.5%
International 5.4% 3.2% 4.5%
Adjusted Operational Sales Growth
THIRD QUARTER 2024 ACTUAL vs. 2023 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 13 of 23 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 3.9% 4.1% 4.0%
U.S. 8.2% 6.7% 7.7%
International (1.7)% 1.6% (0.4)%
WW Currency (1.6) (1.6) (1.6)
U.S. - - -
International (3.8) (3.1) (3.5)
WW Operational 5.5% 5.7% 5.6%
U.S. 8.2% 6.7% 7.7%
International 2.1% 4.7% 3.1%
Shockwave (1.3) (0.5)
U.S. (2.1) (0.7)
International (0.6) (0.2)
All Other Acquisitions and Divestitures (A&D) 0.1 0.3 0.2
U.S. 0.1 0.7 0.3
International 0.1 0.1 0.1
WW Adjusted Operational Ex A&D 5.6% 4.7% 5.3%
U.S. 8.3% 5.3% 7.3%
International 2.2% 4.2% 3.0%
COVID-19 Vaccine 2.4 1.5
U.S. 0.0 0.0
International 5.3 3.2
WW Adjusted Operational Ex A&D & COVID-19 Vaccine 8.0% 4.7% 6.8%
U.S. 8.3% 5.3% 7.3%
International 7.5% 4.2% 6.2%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
NINE MONTHS 2024 ACTUAL vs. 2023 ACTUAL
Segments

-- 14 of 23 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
NINE MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
IMMUNOLOGY
US 3,068	$ 3,193 -3.9% -3.9% - 8,499	$ 8,506 -0.1% -0.1% -
Intl 1,552 1,656 -6.2% -2.1% -4.1% 5,090 4,951 2.8% 7.3% -4.5%
WW 4,621 4,849 -4.7% -3.3% -1.4% 13,590 13,457 1.0% 2.6% -1.6%
REMICADE
US 281 296 -5.4% -5.4% - 778 849 -8.5% -8.5% -
US Exports (3) 27 38 -28.9% -28.9% - 89 112 -20.5% -20.5% -
Intl 112 127 -11.5% -6.5% -5.0% 380 449 -15.4% -11.3% -4.1%
WW 419 461 -9.1% -7.7% -1.4% 1,246 1,410 -11.6% -10.3% -1.3%
SIMPONI / SIMPONI ARIA
US 299 310 -3.7% -3.7% - 820 866 -5.3% -5.3% -
Intl 218 319 -31.8% -23.3% -8.5% 787 829 -5.1% 4.1% -9.2%
WW 516 629 -18.0% -13.6% -4.4% 1,607 1,695 -5.2% -0.7% -4.5%
STELARA
US 1,770 1,912 -7.5% -7.5% - 5,021 5,180 -3.1% -3.1% -
Intl 906 951 -4.8% -2.3% -2.5% 2,991 2,925 2.2% 5.4% -3.2%
WW 2,676 2,864 -6.6% -5.7% -0.9% 8,012 8,105 -1.2% 0.0% -1.2%
TREMFYA
US 691 634 9.1% 9.1% - 1,789 1,490 20.1% 20.1% -
Intl 316 258 22.6% 26.9% -4.3% 932 747 24.7% 29.6% -4.9%
WW 1,007 891 13.0% 14.3% -1.3% 2,721 2,237 21.6% 23.3% -1.7%
OTHER IMMUNOLOGY
US 1 2 -45.6% -45.6% - 3 9 -66.8% -66.8% -
Intl 0 0 - - - 0 0 - - -
WW 1 2 -45.6% -45.6% - 3 9 -66.8% -66.8% -
INFECTIOUS DISEASES
US 365 360 1.5% 1.5% - 1,023 1,147 -10.8% -10.8% -
Intl 471 500 -5.7% -5.1% -0.6% 1,599 2,420 -33.9% -33.4% -0.5%
WW 836 859 -2.7% -2.4% -0.3% 2,622 3,566 -26.5% -26.1% -0.4%
COVID-19 VACCINE
US 0 0 - - - 0 0 - - -
Intl 1 41 -97.7% -98.9% 1.2% 198 1,073 -81.6% -81.6% 0.0%
WW 1 41 -97.7% -98.9% 1.2% 198 1,073 -81.6% -81.6% 0.0%
EDURANT / rilpivirine
US 8 9 -15.8% -15.8% - 24 26 -10.0% -10.0% -
Intl 323 287 12.3% 11.4% 0.9% 926 816 13.5% 13.3% 0.2%
WW 330 297 11.5% 10.6% 0.9% 950 843 12.7% 12.6% 0.1%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 355 345 2.8% 2.8% - 990 1,105 -10.5% -10.5% -
Intl 94 102 -6.9% -3.0% -3.9% 315 310 1.8% 4.3% -2.5%
WW 449 447 0.6% 1.5% -0.9% 1,305 1,415 -7.8% -7.2% -0.6%
OTHER INFECTIOUS DISEASES
US 3 5 -52.2% -52.2% - 10 15 -37.7% -37.7% -
Intl 53 69 -23.2% -20.5% -2.7% 160 220 -27.4% -24.2% -3.2%
WW 55 74 -25.4% -22.9% -2.5% 169 235 -28.0% -25.1% -2.9%
THIRD QUARTER
% Change	% Change

-- 15 of 23 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
NINE MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
NEUROSCIENCE
US 1,094 1,036 5.6% 5.6% - 3,250 3,043 6.8% 6.8% -
Intl 662 706 -6.2% -3.9% -2.3% 2,090 2,296 -8.9% -4.8% -4.1%
WW 1,755 1,742 0.8% 1.7% -0.9% 5,340 5,339 0.0% 1.8% -1.8%
CONCERTA / Methylphenidate
US 26 57 -55.0% -55.0% - 101 191 -47.5% -47.5% -
Intl 117 133 -11.9% -8.5% -3.4% 382 412 -7.3% -2.9% -4.4%
WW 142 189 -24.8% -22.5% -2.3% 482 603 -20.0% -17.0% -3.0%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 780 730 6.8% 6.8% - 2,329 2,164 7.6% 7.6% -
Intl 269 299 -10.1% -8.3% -1.8% 830 940 -11.7% -8.7% -3.0%
WW 1,049 1,029 1.9% 2.4% -0.5% 3,159 3,104 1.8% 2.7% -0.9%
SPRAVATO
US 243 154 56.8% 56.8% - 660 409 61.2% 61.2% -
Intl 42 29 44.6% 47.4% -2.8% 120 74 62.9% 65.0% -2.1%
WW 284 183 54.9% 55.3% -0.4% 780 483 61.5% 61.8% -0.3%
OTHER NEUROSCIENCE
US 46 94 -51.4% -51.4% - 161 278 -42.1% -42.1% -
Intl 235 245 -4.4% -2.0% -2.4% 759 870 -12.8% -7.4% -5.4%
WW 281 340 -17.4% -15.7% -1.7% 920 1,149 -19.9% -15.8% -4.1%
ONCOLOGY
US 2,816 2,219 26.9% 26.9% - 7,835 6,177 26.8% 26.8% -
Intl 2,565 2,313 10.9% 14.3% -3.4% 7,450 6,865 8.5% 12.6% -4.1%
WW 5,380 4,533 18.7% 20.5% -1.8% 15,284 13,043 17.2% 19.3% -2.1%
CARVYKTI
US 258 140 84.9% 84.9% - 565 324 74.6% 74.6% -
Intl 27 12 * * * 63 17 * * *
WW 286 152 87.7% 87.6% 0.1% 629 341 84.3% 84.2% 0.1%
DARZALEX
US 1,684 1,369 23.0% 23.0% - 4,789 3,882 23.4% 23.4% -
Intl 1,332 1,130 17.9% 22.8% -4.9% 3,797 3,312 14.6% 19.9% -5.3%
WW 3,016 2,499 20.7% 22.9% -2.2% 8,586 7,194 19.3% 21.8% -2.5%
ERLEADA
US 337 288 17.1% 17.1% - 940 778 20.8% 20.8% -
Intl 453 342 32.4% 34.0% -1.6% 1,275 961 32.6% 35.6% -3.0%
WW 790 631 25.4% 26.3% -0.9% 2,215 1,740 27.3% 29.0% -1.7%
IMBRUVICA
US 259 264 -1.9% -1.9% - 770 796 -3.2% -3.2% -
Intl 494 545 -9.2% -7.2% -2.0% 1,537 1,681 -8.5% -6.1% -2.4%
WW 753 808 -6.8% -5.5% -1.3% 2,307 2,476 -6.8% -5.2% -1.6%
TECVAYLI
US 105 93 13.5% 13.5% - 310 232 34.0% 34.0% -
Intl 30 19 54.2% 59.4% -5.2% 93 37 * * *
WW 135 112 20.6% 21.4% -0.8% 403 269 49.6% 50.0% -0.4%
ZYTIGA / abiraterone acetate
US 5 16 -66.0% -66.0% - 25 41 -38.0% -38.0% -
Intl 144 199 -27.1% -24.4% -2.7% 470 646 -27.1% -22.8% -4.3%
WW 150 214 -30.0% -27.5% -2.5% 496 686 -27.8% -23.7% -4.1%
OTHER ONCOLOGY
US 168 50 * * - 435 125 * * -
Intl 83 67 24.8% 27.6% -2.8% 214 211 2.0% 4.8% -2.8%
WW 250 117 * * * 649 336 93.4% 95.1% -1.7%
THIRD QUARTER
% Change % Change

-- 16 of 23 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
NINE MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 815 680 20.0% 20.0% - 2,324 1,964 18.4% 18.4% -
Intl 287 274 4.5% 9.7% -5.2% 866 835 3.7% 10.6% -6.9%
WW 1,102 954 15.6% 17.0% -1.4% 3,190 2,798 14.0% 16.1% -2.1%
OPSUMIT
US 406 323 25.4% 25.4% - 1,135 924 22.8% 22.8% -
Intl 165 166 -0.2% 1.7% -1.9% 504 512 -1.6% 2.2% -3.8%
WW 571 490 16.8% 17.4% -0.6% 1,639 1,437 14.1% 15.4% -1.3%
UPTRAVI
US 379 336 12.7% 12.7% - 1,120 978 14.5% 14.5% -
Intl 80 66 21.8% 28.2% -6.4% 232 185 25.5% 33.5% -8.0%
WW 458 402 14.2% 15.2% -1.0% 1,352 1,163 16.3% 17.5% -1.2%
OTHER PULMONARY HYPERTENSION
US 32 20 54.0% 54.0% - 70 61 14.0% 14.0% -
Intl 40 42 -3.9% 12.4% -16.3% 129 137 -5.8% 10.9% -16.7%
WW 72 63 15.0% 25.9% -10.9% 199 199 0.3% 11.9% -11.6%
CARDIOVASCULAR / METABOLISM / OTHER
US 713 763 -6.5% -6.5% - 2,061 2,254 -8.5% -8.5% -
Intl 170 194 -11.9% -10.0% -1.9% 543 580 -6.4% -4.6% -1.8%
WW 884 957 -7.6% -7.2% -0.4% 2,605 2,834 -8.1% -7.7% -0.4%
XARELTO
US 592 625 -5.2% -5.2% - 1,697 1,840 -7.8% -7.8% -
Intl - - - - - - - - - -
WW 592 625 -5.2% -5.2% - 1,697 1,840 -7.8% -7.8% -
OTHER
US 121 139 -12.2% -12.2% - 364 414 -11.9% -11.9% -
Intl 170 194 -11.9% -10.0% -1.9% 543 580 -6.4% -4.6% -1.8%
WW 292 332 -12.0% -10.9% -1.1% 908 994 -8.7% -7.7% -1.0%
TOTAL INNOVATIVE MEDICINE
US 8,871 8,249 7.5% 7.5% - 24,993 23,090 8.2% 8.2% -
Intl 5,709 5,644 1.2% 4.4% -3.2% 17,639 17,947 -1.7% 2.1% -3.8%
WW 14,580	$ 13,893	$ 4.9% 6.3% -1.4% 42,632	$ 41,037 3.9% 5.5% -1.6%
See footnotes at end of schedule
THIRD QUARTER
% Change % Change

-- 17 of 23 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
NINE MONTHS
MEDTECH SEGMENT (2) 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
CARDIOVASCULAR (4)
US 1,148	$ 891 28.6% 28.6% - 3,292	$ 2,662 23.6% 23.6% -
Intl 819 667 22.8% 23.7% -0.9% 2,353 2,019 16.5% 20.5% -4.0%
WW 1,966 1,558 26.2% 26.5% -0.3% 5,645 4,681 20.6% 22.3% -1.7%
ELECTROPHYSIOLOGY
US 660 611 7.9% 7.9% - 2,057 1,791 14.8% 14.8% -
Intl 619 549 12.7% 13.8% -1.1% 1,889 1,658 14.0% 18.2% -4.2%
WW 1,279 1,161 10.2% 10.7% -0.5% 3,946 3,449 14.4% 16.5% -2.1%
ABIOMED
US 293 254 15.4% 15.4% - 905 790 14.5% 14.5% -
Intl 68 57 20.1% 20.1% 0.0% 207 176 17.7% 20.0% -2.3%
WW 362 311 16.3% 16.3% 0.0% 1,112 966 15.1% 15.5% -0.4%
SHOCKWAVE (5)
US 163 - * * - 240 - * * -
Intl 66 - * * - 66 - * * -
WW 229 - * * - 306 - * * -
OTHER CARDIOVASCULAR (4)
US 30 26 16.7% 16.7% - 89 81 10.6% 10.6% -
Intl 66 61 7.7% 7.5% 0.2% 192 186 3.0% 5.7% -2.7%
WW 96 87 10.4% 10.2% 0.2% 281 267 5.3% 7.2% -1.9%
ORTHOPAEDICS
US 1,359 1,349 0.7% 0.7% - 4,229 4,100 3.2% 3.2% -
Intl 832 815 2.0% 2.2% -0.2% 2,614 2,574 1.5% 3.1% -1.6%
WW 2,191 2,164 1.2% 1.3% -0.1% 6,843 6,674 2.5% 3.2% -0.7%
HIPS
US 250 239 4.8% 4.8% - 785 730 7.5% 7.5% -
Intl 131 136 -3.6% -3.2% -0.4% 435 432 0.6% 2.4% -1.8%
WW 381 375 1.7% 1.9% -0.2% 1,220 1,162 5.0% 5.6% -0.6%
KNEES
US 212 207 2.2% 2.2% - 684 654 4.5% 4.5% -
Intl 140 131 6.9% 7.0% -0.1% 463 415 11.5% 12.7% -1.2%
WW 352 338 4.0% 4.1% -0.1% 1,147 1,069 7.2% 7.7% -0.5%
TRAUMA
US 497 488 1.8% 1.8% - 1,499 1,462 2.5% 2.5% -
Intl 265 253 4.2% 4.8% -0.6% 786 775 1.4% 3.0% -1.6%
WW 761 742 2.6% 2.8% -0.2% 2,285 2,238 2.1% 2.7% -0.6%
SPINE, SPORTS & OTHER
US 400 415 -3.6% -3.6% - 1,262 1,254 0.6% 0.6% -
Intl 296 295 0.4% 0.4% 0.0% 930 952 -2.3% -0.6% -1.7%
WW 696 710 -1.9% -2.0% 0.1% 2,191 2,205 -0.6% 0.1% -0.7%
THIRD QUARTER
% Change % Change

-- 18 of 23 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
NINE MONTHS
2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency
SURGERY
US 983 994 -1.1% -1.1% - 2,965 2,984 -0.6% -0.6% -
Intl 1,451 1,483 -2.2% -0.3% -1.9% 4,373 4,522 -3.3% 0.4% -3.7%
WW 2,434 2,479 -1.8% -0.7% -1.1% 7,338 7,507 -2.2% 0.0% -2.2%
ADVANCED
US 448 455 -1.4% -1.4% - 1,360 1,365 -0.4% -0.4% -
Intl 661 709 -6.8% -5.1% -1.7% 1,977 2,139 -7.6% -4.2% -3.4%
WW 1,109 1,164 -4.7% -3.6% -1.1% 3,337 3,504 -4.8% -2.7% -2.1%
GENERAL
US 535 540 -0.9% -0.9% - 1,605 1,619 -0.9% -0.9% -
Intl 791 775 2.1% 4.0% -1.9% 2,397 2,383 0.6% 4.4% -3.8%
WW 1,325 1,314 0.8% 2.0% -1.2% 4,001 4,002 0.0% 2.3% -2.3%
VISION
US 549 512 7.2% 7.2% - 1,619 1,599 1.3% 1.3% -
Intl 751 744 0.9% 1.8% -0.9% 2,224 2,265 -1.8% 1.0% -2.8%
WW 1,300 1,256 3.5% 4.0% -0.5% 3,843 3,864 -0.5% 1.1% -1.6%
CONTACT LENSES / OTHER
US 441 399 10.2% 10.2% - 1,288 1,252 2.8% 2.8% -
Intl 527 529 -0.3% 0.6% -0.9% 1,508 1,568 -3.8% -0.4% -3.4%
WW 968 928 4.2% 4.7% -0.5% 2,796 2,820 -0.9% 1.0% -1.9%
SURGICAL
US 108 112 -3.6% -3.6% - 331 346 -4.4% -4.4% -
Intl 225 216 3.9% 4.7% -0.8% 717 698 2.7% 4.2% -1.5%
WW 333 328 1.3% 1.9% -0.6% 1,048 1,044 0.3% 1.4% -1.1%
TOTAL MEDTECH
US 4,038 3,747 7.8% 7.8% - 12,105 11,345 6.7% 6.7% -
Intl 3,853 3,711 3.9% 5.0% -1.1% 11,564 11,382 1.6% 4.7% -3.1%
WW 7,891	$ 7,458	$ 5.8% 6.4% -0.6% 23,669	$ 22,727 4.1% 5.7% -1.6%
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Reported as U.S. sales
(4) Previously referred to as Interventional Solutions
(5) Acquired on May 31, 2024
THIRD QUARTER
% Change	% Change

-- 19 of 23 --

2024 2023 Total Operations Currency 2024 2023 Total Operations Currency
Innovative Medicine
U.S. 8,871	$ 8,249 7.5 7.5 - 24,993	$ 23,090 8.2 8.2 -
International 5,709 5,644 1.2 4.4 (3.2) 17,639 17,947 (1.7) 2.1 (3.8)
Worldwide 14,580 13,893 4.9 6.3 (1.4) 42,632 41,037 3.9 5.5 (1.6)
COVID-19 Vaccine
U.S. - - - - - - - - - -
International 1 41 (97.7) (98.9) 1.2 198 1,073 (81.6) (81.6) 0.0
Worldwide 1 41 (97.7) (98.9) 1.2 198 1,073 (81.6) (81.6) 0.0
Innovative Medicine excluding COVID-19 Vaccine
U.S. 8,871 8,249 7.5 7.5 - 24,993 23,090 8.2 8.2 -
International 5,708 5,603 1.9 5.2 (3.3) 17,441 16,874 3.4 7.4 (4.0)
Worldwide 14,579 13,852 5.2 6.6 (1.4) 42,434 39,964 6.2 7.9 (1.7)
Worldwide
U.S. 12,909 11,996 7.6 7.6 - 37,098 34,435 7.7 7.7 -
International 9,562 9,355 2.2 4.6 (2.4) 29,203 29,329 (0.4) 3.1 (3.5)
Worldwide 22,471 21,351 5.2 6.3 (1.1) 66,301 63,764 4.0 5.6 (1.6)
COVID-19 Vaccine
U.S. - - - - - - - - - -
International 1 41 (97.7) (98.9) 1.2 198 1,073 (81.6) (81.6) 0.0
Worldwide 1 41 (97.7) (98.9) 1.2 198 1,073 (81.6) (81.6) 0.0
Worldwide
U.S. 12,909 11,996 7.6 7.6 - 37,098 34,435 7.7 7.7 -
International 9,561 9,314 2.7 5.1 (2.4) 29,005 28,256 2.7 6.3 (3.6)
Worldwide excluding COVID-19 Vaccine 22,470	$ 21,310 5.4 6.5 (1.1) 66,103	$ 62,691 5.4 7.1 (1.7)
Europe 4,914	$ 4,727 4.0 3.0 1.0 15,291	$ 15,448 (1.0) (0.7) (0.3)
Europe COVID-19 Vaccine Sales 1 41 (97.7) (98.9) 1.2 198 1,073 (81.6) (81.6) 0.0
Europe excluding COVID-19 Vaccine Sales 4,913	$ 4,686 4.8 3.8 1.0 15,093	$ 14,375 5.0 5.3 (0.3)
Percent Change
THIRD QUARTER NINE MONTHS
Percent Change
Supplemental Sales Information (Unaudited)
(Dollars in Millions)

-- 20 of 23 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2024 2023 2024 2023 2024 2023 2024 2023
Reported Income Before Tax by Segment From Continuing Operations $ 4,482 4,794 1,059 1,185 (2,203) (762) 3,338 5,217
% to Sales 30.7% 34.5% 13.4% 15.9% -9.8% -3.6% 14.9% 24.4%
Intangible asset amortization expense 695 749 476 383 - - 1,171 1,132
In-process research and development impairments - 206 - - - - - 206
Litigation related 356 (32) 19 (19) 2,013 - 2,388 (51)
Loss/(gain) on securities (41) 398 4 (38) - 645 (37) 1,005
Restructuring related 19 149 28 235 - - 47 384
Acquisition, integration and divestiture related 6 - 277 22 45 - 328 22
Medical Device Regulation - - 38 74 - - 38 74
COVID-19 Vaccine related costs 4 44 - - - - 4 44
Adjusted Income Before Tax by Segment From Continuing Operations $ 5,521 6,308 1,901 1,842 (145) (117) 7,277 8,033
% to Sales 37.9% 45.4% 24.1% 24.7% -0.6% -0.5% 32.4% 37.6%
Estimated as of 10/15/2024
As Reported Research and development expense* $ 4,213 2,778 739 669 4,952 3,447
% to Sales 28.9% 20.0% 9.4% 9.0% 22.0% 16.2%
*Includes payment to secure the global rights for NM26 Bi-specific Antibody in Q3 2024 1,250 1,250
Q3 QTD - Income Before Tax and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine MedTech Unallocated Worldwide Total

-- 21 of 23 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2024 2023 2024 2023 2024 2023 2024 2023
Reported Income Before Tax by Segment From Continuing Operations $ 14,910 14,008 3,668 4,265 (5,778) (8,037) 12,800 10,236
% to Sales 35.0% 34.1% 15.5% 18.8% -8.7% -12.6% 19.3% 16.1%
Intangible asset amortization expense 2,087 2,236 1,268 1,148 - - 3,355 3,384
In-process research and development impairments 194 206 - 49 - - 194 255
Litigation related 399 (125) 15 41 5,052 7,070 5,466 6,986
Loss/(gain) on securities (26) 474 48 (43) 352 645 374 1,076
Restructuring related 100 424 107 235 - - 207 659
Acquisition, integration and divestiture related 54 - 747 102 127 - 928 102
Medical Device Regulation - - 157 223 - - 157 223
COVID-19 Vaccine related costs 77 653 - - - - 77 653
Adjusted Income Before Tax by Segment From Continuing Operations $ 17,795 17,876 6,010 6,020 (247) (322) 23,558 23,574
% to Sales 41.7% 43.6% 25.4% 26.5% -0.4% -0.5% 35.5% 37.0%
Estimated as of 10/15/2024
As Reported Research and development expense* $ 9,831 8,604 2,103 2,001 11,934 10,605
% to Sales 23.1% 21.0% 8.9% 8.8% 18.0% 16.6%
*Includes payment to secure the global rights for NM26 Bi-specific Antibody in Q3 2024 1,250 1,250
Q3 YTD - Income Before Tax and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine MedTech Unallocated Worldwide Total

-- 22 of 23 --

Third Quarter
Sept. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Third Quarter
Sept. 29, 2024
Non-GAAP
Cost of products sold 6,963	$ (1,171) (6) (156) (16) (2) - 5,612
Selling, marketing and admin expenses 5,478 (3) 5,475
Research and development expense 4,952 (36) (19) (2) 4,895
Other (Income) / Expense 1,798 - (2,388) - (136) 37 - (689)
In-process research and development impairments - - - -
Restructuring 41 (41) -
Provision for taxes on income 644 169 527 - 9 59 (9) 6 1 (5) 1,401
Net Earnings from Continuing Operations 2,694 1,002 1,861 - 38 269 (28) 32 3 5 5,876
Third Quarter
Oct. 1, 2023
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Third Quarter
Oct. 1, 2023
Non-GAAP
Cost of products sold 6,606	$ (1,132) (226) (34) (9) - 5,205
Selling, marketing and admin expenses 5,400 (6) 5,394
Research and development expense 3,447 - (33) (36) 3,378
Other (Income) / Expense 499 - 51 - (22) (1,005) - (477)
In-process research and development impairments 206 (206) -
Restructuring 158 (158) -
Provision for taxes on income 908 178 (12) 46 72 5 167 14 12 (134) 1,256
Net Earnings from Continuing Operations 4,309 954 (39) 160 312 17 838 59 33 134 6,777
Nine Months
Sept. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Nine Months
Sept. 29, 2024
Non-GAAP
Cost of products sold 20,343	$ (3,355) (15) (206) (66) (8) 16,693
Selling, marketing and admin expenses 16,416 (12) - 16,404
Research and development expense 11,934 (69) (79) (19) 11,767
Other (Income) / Expense 4,855 - (5,466) - (653) (374) (50) (1,688)
In-process research and development impairments 194 (194) - - - - -
Restructuring 192 (192) -
Provision for taxes on income 2,165 473 1,224 43 42 222 5 29 17 42 4,262
Net Earnings from Continuing Operations 10,635 2,882 4,242 151 165 706 369 128 60 (42) 19,296
Nine Months
Oct. 1, 2023
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Medical Device
Regulation
Nine Months
Oct 1, 2023
Non-GAAP
Cost of products sold 19,755	$ (3,380) (226) (91) (177) 15,881
Selling, marketing and admin expenses 15,702 (21) 15,681
Research and development expense 10,605 (16) (111) (98) 10,380
Other (Income) / Expense 7,055 (4) (6,986) - (86) (1,076) (378) (1,475)
In-process research and development impairments 255 (255) - -
Restructuring 433 (433) -
Provision for taxes on income 1,042 532 1,639 57 141 22 182 41 155 (84) 3,727
Net Earnings from Continuing Operations 9,194 2,852 5,347 198 518 80 894 182 498 84 19,847
Year to Date
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
impairments
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
In-process
research and
development
impairments
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
In-process
research and
development
impairments
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
In-process
research and
development
impairments
Acquisition, integration
and divestiture related
(Loss)/gain on
securities
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related

-- 23 of 23 --